Lakefront Biotherapeutics (LKFT) Accumulated Expenses (2013 - 2018)
Lakefront Biotherapeutics (LKFT) posted quarterly Accumulated Expenses of $23280.9 for Q4 2025, down 98.0% year-over-year from $1.2 million in Q4 2024, and down 98.0% quarter-over-quarter from $1.2 million in Q4 2024.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Accumulated Expenses (2013 - 2018) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Accumulated Expenses for 8 consecutive years, with $23280.9 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses fell 98.0% year-over-year to $23280.9; the TTM figure through Dec 2025 stood at $23280.9 (down 98.0% YoY), while the FY2025 annual figure was $23280.9, down 98.0% from the prior year.
- Accumulated Expenses eased to $23280.9 in Q4 2025 per LKFT's latest filing, from $1.2 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.2 million in Q4 2024 and bottomed at $23280.9 in Q4 2025.
- Historically, Accumulated Expenses has averaged $593267.4 across 3 years, with a median of $589615.1 in 2023.
- Annual changes were most pronounced in 2024 — Accumulated Expenses surged 97.91% — and 2025, when it slumped 98.0%.
- Lakefront Biotherapeutics' Accumulated Expenses stood at $589615.1 in 2023, then soared by 97.91% to $1.2 million in 2024, then plunged by 98.0% to $23280.9 in 2025.
- Business Quant data shows LKFT's Accumulated Expenses at $23280.9 in Q4 2025, $1.2 million in Q4 2024, and $589615.1 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 1.01 Mn |
| Jun 30, 2018 | 1.03 Bn |
| Mar 31, 2018 | 1.16 Mn |
| Dec 31, 2017 | 1.36 Mn |
| Jun 30, 2017 | 1.15 Mn |
| Mar 31, 2017 | 981,239.75 |
| Dec 31, 2016 | 668,349.29 |
| Jun 30, 2016 | 813,510.02 |
| Dec 31, 2015 | 537,097.47 |
| Dec 31, 2014 | 731,152.59 |
| Dec 31, 2013 | 5.25 Mn |